Page last updated: 2024-12-06

amantadine hydrochloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Amantadine hydrochloride is an antiviral medication primarily used to treat influenza A infections. It is also used to treat Parkinson's disease, restless legs syndrome, and certain types of dystonia. Amantadine is a synthetic compound that was first synthesized in the 1960s. It works by blocking the M2 protein ion channel of the influenza A virus, preventing the virus from entering and replicating inside host cells. Amantadine is well-tolerated by most patients, but can cause side effects such as nausea, dizziness, and insomnia. It has been studied extensively for its potential to treat a variety of neurological disorders, and remains an important medication in the treatment of influenza A infections and Parkinson's disease. However, the emergence of influenza A strains resistant to amantadine has limited its effectiveness as an antiviral agent.'

hasubanonine: from Stephania japonica; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID64150
CHEMBL ID1569
CHEBI ID2619
SCHEMBL ID40713
MeSH IDM0330750
PubMed CID442246
CHEMBL ID1724728
CHEBI ID5629
SCHEMBL ID518671
MeSH IDM0330750

Synonyms (178)

Synonym
midantan
adamantanamine hydrochloride
gp 38026
exp 105-1
adamantylamine hydrochloride
influenol
adamantine hydrochloride
tricyclo[3.3.1.13, hydrochloride
midantane
trivaline
nsc 83653
amantan
mydantane
nsc-83653
aminoadamantane hydrochloride
amazolon
wln: l66 b6 a b- c 1b itj bz &gh
amantadine hcl
virofral
ai3-52211
einecs 211-560-2
tricyclo(3.3.1.13,7)decan-1-amine, hydrochloride
virasol
tricyclo(3.3.1.1(sup 3,7))decan-1-amine, hydrochloride
1-aminoadamantene hydrochloride
1-aminoadamantane hydrochloride
CHEBI:2619 ,
adamantan-1-aminium chloride
1-adamantylamine hydrochloride
1-adamantanamine hydrochloride
smr000059204
MLS000028731 ,
exp-105-1
EU-0100004
viregyt
1-adamantanamine, hydrochloride
virosol
symmetrel
nsc83653
665-66-7
amantadine hydrochloride ,
C07939
gocovri (tn)
symmetrel (tn)
D00777
osmolex er (tn)
amantadine hydrochloride (jp17/usp)
NCGC00093531-03
NCGC00093531-02
SPECTRUM1500110
NCGC00093531-04
NCGC00093531-01
MLS002153257
tricyclo[3.3.1.1 3,7]decan-1-amine hydrochloride
A 1260
A0588
hydrochloride, amantadine
cerebramed
mantadix
adamantamine hydrochloride
ads-5101
ads-5102
nurelin
lysovir
hofcomant
adamantan-1-amine hydrochloride
osmolex
CHEMBL1569
HMS1920A19
1-adamantylammonium;1-adamantanamine hcl
A835493
pharmakon1600-01500110
nsc-755860
nsc755860
AKOS015951188
1-adamantanamine hcl
CCG-38899
amantadine hydrochloride [usan:usp:jan]
tricyclo(3.3.1.13,7)decan-1-amine, hydrochloride (1:1)
m6q1eo9td0 ,
ec 211-560-2
unii-m6q1eo9td0
mantadine
FT-0622248
LP00004
amantadine hydrochloride [mi]
amantadine hydrochloride [orange book]
amantadine hydrochloride [usan]
amantadine hydrochloride [mart.]
amantadine hydrochloride [usp-rs]
amantadine hydrochloride [usp monograph]
amantadine hydrochloride [ep monograph]
amantadine hydrochloride [vandf]
amantadine hydrochloride [jan]
amantadine hydrochloride [who-dd]
AKOS015900347
MLS003899199
smr001370746
S2451
HY-B0402A
amantadine (hydrochloride) ,
WOLHOYHSEKDWQH-UHFFFAOYSA-N
adamantyl amine hydrochloride
1-aminoada- mantane hydrochloride
NC00489
SCHEMBL40713
tox21_500004
NCGC00260689-01
J-650095
J-650235
(3r,5s,7s)-adamantan-1-amine hydrochloride
Q-200621
1-adamantanaminehydrochloride
STR01017
amantadine hydrochloride, pharmaceutical secondary standard; certified reference material
c10h17n.hcl
HB0109
OPERA_ID_671
F3111-1111
mfcd00074723
adamantan-1-amine;hydrochloride
amantadine hydrochloride, european pharmacopoeia (ep) reference standard
AC-8689
SR-01000075353-1
sr-01000075353
amantadine hydrochloride, united states pharmacopeia (usp) reference standard
tricyclo[3.3.1.13,7]decan-1-amine, hydrochloride
SW219892-1
n04bb01
adamin
mantadan
adamine
tricyclo[3.3.1.13,7]decan-1-amine hydrochloride
DTXSID50874031
amantadinehydrochloride
F15409
amantadine hydrochloride (symmetrel)
Q27105739
1-aminoadamantane hydrochloride; 1-adamantanamine hydrochloride; 1-adamantylamine hydrochloride
BCP11857
AMY3568
1-adamantanamine hydrochloride;1-adamantylamine hydrochloride;1-aminoadamantane hydrochloride
665-66-7 (hcl)
adamantan-1-aminehydrochloride
BA166177
EN300-17255
tricyclo(3.3.1.1(3,7))decan-1-aminium chloride
amantadine hydrochloride (ep monograph)
osmolex er
amantadine hydrochloride (usp-rs)
amantadine hydrochloride (usan:usp:jan)
tricyclo(3.3.1.13,7)dec-1-ylamine monohydrochloride
amantadine hydrochloride (mart.)
amantadine hydrochloride (usp monograph)
Z1522567174
1805-85-2
C09459
hasubanonine
MLS002473203 ,
hasbanonine
smr001397292
AC1L9CHH ,
hasubanan-6-one, 7,8-didehydro-3,4,7,8-tetramethoxy-17-methyl-
9tlc4wa6xc ,
7,8-didehydro-3,4,7,8-tetramethoxy-17-methylhasubanan-6-one
unii-9tlc4wa6xc
HMS2225B14
HMS3328J03
SCHEMBL518671
CHEBI:5629 ,
(-)-hasubanonine
hasubanonine [mi]
o-methylaknadinine
CHEMBL1724728
surecn518671
DTXSID50170969
Q5680713
(1s,10s)-3,4,11,12-tetramethoxy-17-methyl-17-azatetracyclo[8.4.3.01,10.02,7]heptadeca-2(7),3,5,11-tetraen-13-one

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
dopamine agonistA drug that binds to and activates dopamine receptors.
NMDA receptor antagonistAny substance that inhibits the action of N-methyl-D-aspartate (NMDA) receptors. They tend to induce a state known as dissociative anesthesia, marked by catalepsy, amnesia, and analgesia, while side effects can include hallucinations, nightmares, and confusion. Due to their psychotomimetic effects, many NMDA receptor antagonists are used as recreational drugs.
antiviral agentA substance that destroys or inhibits replication of viruses.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
hydrochlorideA salt formally resulting from the reaction of hydrochloric acid with an organic base.
isoquinoline alkaloidAny alkaloid that has a structure based on an isoquinoline nucleus. They are derived from the amino acids like tyrosine and phenylalanine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (26)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency5.01190.044717.8581100.0000AID485294
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency7.94330.28189.721235.4813AID2326
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency1.77830.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.01120.540617.639296.1227AID2364; AID2528
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency37.933023.934123.934123.9341AID1967
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency0.00890.010039.53711,122.0200AID1479
transcriptional regulator ERG isoform 3Homo sapiens (human)Potency15.84890.794321.275750.1187AID624246
importin subunit beta-1 isoform 1Homo sapiens (human)Potency66.20255.804836.130665.1308AID540253; AID540263
DNA polymerase betaHomo sapiens (human)Potency50.11870.022421.010289.1251AID485314
snurportin-1Homo sapiens (human)Potency66.20255.804836.130665.1308AID540253; AID540263
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency6.51315.804816.996225.9290AID540253
gemininHomo sapiens (human)Potency0.89130.004611.374133.4983AID624297
survival motor neuron protein isoform dHomo sapiens (human)Potency1.58490.125912.234435.4813AID1458
lamin isoform A-delta10Homo sapiens (human)Potency0.00450.891312.067628.1838AID1487
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency32.64270.00419.984825.9290AID504444
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency7.94330.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency7.94330.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency7.94330.15855.287912.5893AID540303
gemininHomo sapiens (human)Potency14.54930.004611.374133.4983AID624296; AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)IC50 (µMol)216.70000.00071.600310.0000AID410125; AID410126
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)IC50 (µMol)216.70000.00071.630610.0000AID410125; AID410126
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)IC50 (µMol)216.70000.00061.525710.0000AID410125; AID410126
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)IC50 (µMol)216.70000.00071.747210.0000AID410125; AID410126
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)IC50 (µMol)216.70000.00071.741110.0000AID410125; AID410126
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)IC50 (µMol)216.70000.00071.741110.0000AID410125; AID410126
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)IC50 (µMol)216.70000.00071.741110.0000AID410125; AID410126
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (77)

Assay IDTitleYearJournalArticle
AID1167600Antibacterial activity against Escherichia coli ATCC 25922 after 24 hrs by broth dilution method2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Discovery and structure-activity relationship studies of irreversible benzisothiazolinone-based inhibitors against Staphylococcus aureus sortase A transpeptidase.
AID410126Inhibition of NMDA receptor in rat cerebellar granule neurons assessed as NMDA-induced intracellular calcium increase2008Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23
Comparisons of the influenza virus A M2 channel binding affinities, anti-influenza virus potencies and NMDA antagonistic activities of 2-alkyl-2-aminoadamantanes and analogues.
AID1167599Antibacterial activity against Staphylococcus epidermidis ATCC 12228 after 24 hrs by broth dilution method2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Discovery and structure-activity relationship studies of irreversible benzisothiazolinone-based inhibitors against Staphylococcus aureus sortase A transpeptidase.
AID1145322Antiviral activity against Newcastle disease virus Miyadera infected in CEF assessed as suppression of <= 1% hemagglutinating activity by tube assay1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Biologically active polycycloalkanes. 2. Antiviral 4-homoisotwistane derivatives.
AID410127Antiviral activity against influenza A virus A/Japan/305/57 H2N2 in MDCK cells assessed as reduction of virus-induced cytopathogenicity2008Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23
Comparisons of the influenza virus A M2 channel binding affinities, anti-influenza virus potencies and NMDA antagonistic activities of 2-alkyl-2-aminoadamantanes and analogues.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID235882Ratio of MIC50 to MTC50 against influenza A1995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
Synthesis of substituted 1-norbornylamines with antiviral activity.
AID410129Antiviral activity against influenza B virus B/Hong kong/05/1972 in MDCK cells assessed as reduction of virus-induced cytopathogenicity2008Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23
Comparisons of the influenza virus A M2 channel binding affinities, anti-influenza virus potencies and NMDA antagonistic activities of 2-alkyl-2-aminoadamantanes and analogues.
AID105798Minimum inhibitory concentration against influenza A virus, in MDCK cells from dog kidney1995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
Synthesis of substituted 1-norbornylamines with antiviral activity.
AID1149824Cytotoxicity against chick embryo fibroblasts after 24 hrs by microscopic analysis1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Biological active polycycloalkanes. 4. Phosphoric esters of trimethylenenorbornyl alcohols.
AID1167601Cytotoxicity against Swiss mouse NIH/3T3 cells after 48 hrs by MTT assay2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Discovery and structure-activity relationship studies of irreversible benzisothiazolinone-based inhibitors against Staphylococcus aureus sortase A transpeptidase.
AID315461Antitrypanosomal activity against Trypanosoma brucei 427 at pH 7.42008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Design, synthesis, and trypanocidal activity of new aminoadamantane derivatives.
AID410125Inhibition of NMDA receptor in rat cerebellar granule neurons assessed as glutamate-induced intracellular calcium increase2008Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23
Comparisons of the influenza virus A M2 channel binding affinities, anti-influenza virus potencies and NMDA antagonistic activities of 2-alkyl-2-aminoadamantanes and analogues.
AID410124Binding affinity to influenza A virus A/chicken/Germany/27 H7N7 weybridge strain M2 ion channel expressed in Escherichia coli2008Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23
Comparisons of the influenza virus A M2 channel binding affinities, anti-influenza virus potencies and NMDA antagonistic activities of 2-alkyl-2-aminoadamantanes and analogues.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID410130Cytotoxicity against MDCK cells assessed as detectable alteration of normal cell morphology2008Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23
Comparisons of the influenza virus A M2 channel binding affinities, anti-influenza virus potencies and NMDA antagonistic activities of 2-alkyl-2-aminoadamantanes and analogues.
AID668906Inhibition of Influenza A Virus M2 proton channel S31N mutant expressed in Xenopus laevis oocytes at 100 uM after 2 mins by two-electrode patch clamp assay2011ACS medicinal chemistry letters, Apr-14, Volume: 2, Issue:4
Exploring the Requirements for the Hydrophobic Scaffold and Polar Amine in inhibitors of M2 from Influenza A Virus.
AID668905Inhibition of Influenza A Virus M2 proton channel V27A mutant expressed in Xenopus laevis oocytes at 100 uM after 2 mins by two-electrode patch clamp assay2011ACS medicinal chemistry letters, Apr-14, Volume: 2, Issue:4
Exploring the Requirements for the Hydrophobic Scaffold and Polar Amine in inhibitors of M2 from Influenza A Virus.
AID1167598Antibacterial activity against Staphylococcus aureus ATCC 25904 after 24 hrs by broth dilution method2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Discovery and structure-activity relationship studies of irreversible benzisothiazolinone-based inhibitors against Staphylococcus aureus sortase A transpeptidase.
AID1167597Inhibition of Staphylococcus aureus sortase A using dabcyl-QALPETGEE-edans as substrate incubated for 1 hr prior to substrate addition measured at 1 min interval for 1 hr by FRET analysis2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Discovery and structure-activity relationship studies of irreversible benzisothiazolinone-based inhibitors against Staphylococcus aureus sortase A transpeptidase.
AID292962Antiviral activity against influenza A virus (H3N2)-induced cytopathogenicity in MDCK cells by MTS method2007Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3
Influence of an additional 2-amino substituent of the 1-aminoethyl pharmacophore group on the potency of rimantadine against influenza virus A.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1145323Cytotoxicity against CEF after 24 hrs by microscopic analysis1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Biologically active polycycloalkanes. 2. Antiviral 4-homoisotwistane derivatives.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID292963Cytotoxicity against MDCK cells2007Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3
Influence of an additional 2-amino substituent of the 1-aminoethyl pharmacophore group on the potency of rimantadine against influenza virus A.
AID410128Antiviral activity against influenza A virus H3N2 X31(A/Hong kong/1/68 x A/Puerto Rico/8/34 reassortant ) in MDCK cells assessed as reduction of virus-induced cytopathogenicity2008Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23
Comparisons of the influenza virus A M2 channel binding affinities, anti-influenza virus potencies and NMDA antagonistic activities of 2-alkyl-2-aminoadamantanes and analogues.
AID668904Inhibition of Influenza A Virus M2 proton channel expressed in Xenopus laevis oocytes after 2 mins by two-electrode patch clamp assay2011ACS medicinal chemistry letters, Apr-14, Volume: 2, Issue:4
Exploring the Requirements for the Hydrophobic Scaffold and Polar Amine in inhibitors of M2 from Influenza A Virus.
AID668903Inhibition of Influenza A Virus M2 proton channel expressed in Xenopus laevis oocytes at 100 uM after 2 mins by two-electrode patch clamp assay2011ACS medicinal chemistry letters, Apr-14, Volume: 2, Issue:4
Exploring the Requirements for the Hydrophobic Scaffold and Polar Amine in inhibitors of M2 from Influenza A Virus.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID105807Minimum toxic concentration against influenza A virus, in MDCK cells from dog kidney1995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
Synthesis of substituted 1-norbornylamines with antiviral activity.
AID1149823Antiviral activity against Newcastle disease virus infected in chick embryo fibroblasts assessed as suppression of virus multiplication to 1% by measuring hemagglutinating activity by tube assay method1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Biological active polycycloalkanes. 4. Phosphoric esters of trimethylenenorbornyl alcohols.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (29)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (10.34)18.7374
1990's1 (3.45)18.2507
2000's8 (27.59)29.6817
2010's14 (48.28)24.3611
2020's3 (10.34)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 62.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index62.87 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index5.49 (4.65)
Search Engine Demand Index101.44 (26.88)
Search Engine Supply Index2.04 (0.95)

This Compound (62.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews1 (4.17%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other23 (95.83%)84.16%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]